Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2005 4
2006 3
2007 6
2008 1
2009 3
2010 2
2011 3
2012 3
2013 2
2014 4
2015 5
2016 3
2017 2
2018 2
2019 5
2020 9
2021 6
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Chi KN, et al. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23. J Clin Oncol. 2023. PMID: 36952634 Free PMC article. Clinical Trial.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Khorana AA, et al. N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. N Engl J Med. 2019. PMID: 30786186 Clinical Trial.
Intratumoral Heterogeneity in Uveal Melanoma.
Fonseca C, Pinto-Proença R, Bergeron S, Pires LM, Fernandes J, Carreira IM, Burnier MN, Proença R. Fonseca C, et al. Among authors: pires lm. Ocul Oncol Pathol. 2021 Mar;7(1):17-25. doi: 10.1159/000508517. Epub 2020 Aug 25. Ocul Oncol Pathol. 2021. PMID: 33796512 Free PMC article.
Sleep effort and its measurement: A scoping review.
Marques DR, Pires L, Broomfield NM, Espie CA. Marques DR, et al. Among authors: pires l. J Sleep Res. 2024 Apr 6:e14206. doi: 10.1111/jsr.14206. Online ahead of print. J Sleep Res. 2024. PMID: 38581186 Review.
Genomic characterisation of multiple myeloma: study of a Portuguese cohort.
Couto Oliveira A, Ribeiro IP, Pires LM, Gonçalves AC, Paiva A, Geraldes C, Roque A, Sarmento-Ribeiro AB, Barbosa de Melo J, Carreira IM. Couto Oliveira A, et al. Among authors: pires lm. J Clin Pathol. 2022 Jun;75(6):422-425. doi: 10.1136/jclinpath-2020-207204. Epub 2021 Mar 2. J Clin Pathol. 2022. PMID: 33653728
73 results